Computational and Experimental Analysis of Sophora alopecuroides L. Chloroform Fraction: Active Components and Anti-Breast Cancer Resistance Mechanisms
Molecules · 2026
DOI: 10.3390/molecules31040660 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Rui Xi und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China. Hauptthemen laut MEDLINE: Sophora, Plant Extracts, Drug Resistance, Neoplasm, Chloroform. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Natural Science Foundation of China, Science & Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
We discovered that the chloroform extracted from Sophora alopecuroides L. exhibited the capacity to counteract multidrug resistance in breast cancer significantly. However, the precise active ingredients and their underlying mechanisms of action remain to be elucidated, necessitating the urgent undertaking of in-depth studies. In this study, an extract of Sophora alopecuroides L. was obtained through ethanol extraction and chloroform solvent extraction. Subsequent isolation and multi-round screening using MCF-7/ADR cells yielded the highly active chloroform derivative SaL-30. The active compound group of Sophora alopecuroides L. (SACG), consisting of 13 compounds, was confirmed by HPLC-QTOF-MS/MS and compositional screening. Network pharmacological analysis and molecular docking technology demonstrated that SACG reversed breast cancer resistance through an intricate multi-component (flavonoids/alkaloids), multi-target (AKT1/TNF/CDK2), and multi-pathway (PI3K-AKT/FoxO/MAPK) synergistic mode of action, with the PI3K-AKT pathway acting as the core regulator. Cell experiments further demonstrate that SaL-30 has strong toxicity against MCF-7/ADR by cellular assay, with an IC50 value of 8.941 ± 0.327 µg/mL and a synergistic index of CI = 0.3258, exhibiting a strong synergistic anti-breast cancer effect when co-administered with Adriamycin. These findings provide a theoretical foundation for elucidating the anti-drug resistance mechanism of Sophora alopecuroides L.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai 201620, China.
- Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Noncoding RNA, Institute for Frontier Medical Technology, Shanghai University of Engineering Science, Shanghai 201620, China.
- School of Medicine, Xizang Minzu University, Wenhui Road East, Weicheng District, Xianyang 712082, China.
- Engineering Research Center of Tibetan Medicine Detection Technology, Ministry of Education, Xianyang 712082, China.
ORCID-Profile: Rui Xi
Förderung
- The National Natural Science Foundation of China
- Science & Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Xi, R., Yin, X., Xiao, C., Chen, H., Lu, Y., Zhao, Q., Shi, D., & Sun, F. (2026). Computational and Experimental Analysis of Sophora alopecuroides L. Chloroform Fraction: Active Components and Anti-Breast Cancer Resistance Mechanisms. Molecules. https://doi.org/10.3390/molecules31040660
Vancouver
Xi R, Yin X, Xiao C, Chen H, Lu Y, Zhao Q, et al. Computational and Experimental Analysis of Sophora alopecuroides L. Chloroform Fraction: Active Components and Anti-Breast Cancer Resistance Mechanisms. Molecules. 2026. doi:10.3390/molecules31040660
BibTeX
@article{Xi2026,
author = {Xi, Rui and Yin, Xiaoying and Xiao, Chuangchuang and Chen, Haoran and Lu, Yang and Zhao, Qin and Shi, Daming and Sun, Fangyun},
title = {Computational and Experimental Analysis of Sophora alopecuroides L. Chloroform Fraction: Active Components and Anti-Breast Cancer Resistance Mechanisms},
journal = {Molecules},
year = {2026},
doi = {10.3390/molecules31040660}
}
EUVIMED